688289.SHG Sansure Biotech Inc
- Market cap
- CNY 9.15B
- P/E
- 83.8x
- P/B
- 1.29x
- ROE
- 2.0%
- Dividend yield
- 3.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688289.SHG undervalued?
Graham number688289.SHG trades 119.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sansure Biotech Inc fundamental analysis
No fundamental analysis for Sansure Biotech Inc yet.
Sansure Biotech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers respiratory tract infections, reproductive tract infections, blood-borne infections, gastrointestinal infections, vector-borne diseases and others, DNA/RNA extraction reagents, sample storage reagent, extraction instruments, PCR instruments, mPOCT. The company provides nucleic acid extraction or purification kits, multi-type s…
Full company profileSansure Biotech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sansure Biotech Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 225M | 303M | 365M | 4.76B | 4.51B | 6.45B | 1.01B | 1.46B | 1.65B | 1.67B |
| Gross Profit | 111M | 177M | 237M | 3.79B | 3.23B | 3.54B | 726M | 1.18B | 1.65B | 1.14B |
| Operating Income | -27.7M | 11.7M | 47.5M | 3.09B | 2.62B | 2.34B | 427M | 278M | 202M | 72.4M |
| EBITDA | 38.4M | 30.9M | 66.7M | 3.10B | 2.66B | 2.39B | 517M | 420M | 316M | 146M |
| Net Income | -10.7M | 6.76M | 39.5M | 2.62B | 2.24B | 1.94B | 364M | 276M | 198M | 139M |
| EPS | -0.03 | 0.02 | 0.07 | 4.74 | 3.81 | 3.31 | 0.62 | 0.47 | 0.34 | 0.24 |
| Balance Sheet | ||||||||||
| Total Assets | 566M | 552M | 642M | 5.45B | 7.09B | 9.17B | 8.45B | 8.60B | 9.53B | 9.59B |
| Total Liabilities | 187M | 156M | 85.0M | 709M | 709M | 1.66B | 1.03B | 1.26B | -7.22B | 2.53B |
| Shareholders' Equity | 379M | 396M | 557M | 4.75B | 6.37B | 7.50B | 7.20B | 7.24B | 7.22B | 6.96B |
| Cash & Short-term Investments | 39.9M | 127M | 165M | 4.19B | 4.68B | 5.66B | 4.78B | 4.73B | 4.01B | 3.62B |
| Total Debt | - | - | - | 55.0M | 14.9M | 27.9M | 27.2M | 418M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -61.4M | 10.1M | 22.4M | 2.64B | 1.88B | 2.56B | 113M | 274M | 184M | - |
| Capital Expenditure | 20.7M | 32.9M | 34.1M | 109M | 373M | 559M | 391M | 421M | 370M | 204M |
| Free Cash Flow | -82.1M | -22.8M | -11.7M | 2.53B | 1.50B | 2.00B | -348M | -147M | -186M | -243M |
| Ratios | ||||||||||
| ROE | -2.8% | 1.7% | 7.1% | 55.1% | 35.2% | 25.8% | 5.1% | 3.8% | 2.7% | 2.0% |
| ROA | -1.9% | 1.2% | 6.1% | 48.0% | 31.6% | 21.1% | 4.3% | 3.2% | 2.1% | 1.4% |
| Net Profit Margin | -4.7% | 2.2% | 10.8% | 54.9% | 49.7% | 30.0% | 36.1% | 18.9% | 12.0% | 8.3% |
| Debt to Equity | - | - | - | 0.01x | 0.00x | 0.00x | 0.00x | 0.06x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sansure Biotech Inc dividends
- Dividend yield
- 3.65%
- Forward dividend
- 0.53 CNY
- Payout ratio
- 168.4%
- Ex-dividend date
- Oct 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 334M | 0.57 | 168.4% |
| 2024 | CNY 268M | 0.46 | 97.4% |
| 2023 | CNY 400M | 0.68 | 110.0% |
| 2022 | CNY 647M | 1.11 | 33.4% |
| 2021 | CNY 449M | 0.76 | 20.0% |
| 2020 | CNY 300M | 0.54 | 11.5% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | 5.58M | 0.02 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.48:1 on Jun 1, 2022.
Who owns Sansure Biotech Inc
- Insiders 47.39%
- Institutions 5.97%
- Public & others 46.64%
- Shares outstanding 575M
- Free float 296M
Sansure Biotech Inc company profile
- Company name
- Sansure Biotech Inc
- Ticker
- 688289.SHG
- ISIN
- CNE1000043J1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 2,128
- Fiscal year end
- December
- Address
- No. 680, Lusong Road, Changsha, China, 410205
- Phone
- 86 731 8888 3176
- Website
- sansure.com.cn
About Sansure Biotech Inc
Sansure Biotech Inc. researches and develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. It offers respiratory tract infections, reproductive tract infections, blood-borne infections, gastrointestinal infections, vector-borne diseases and others, DNA/RNA extraction reagents, sample storage reagent, extraction instruments, PCR instruments, mPOCT. The company provides nucleic acid extraction or purification kits, multi-type sample DNA/RNA extraction-purification kits, and sample release reagents; sample storage reagents for SARS-CoV-2; extraction instruments and systems; and PCR instruments comprising real-time quantitative thermal cyclers, portable molecule workstations, and real-time PCR systems. The company was founded in 2008 and is headquartered in Changsha, China.
Sansure Biotech Inc management
10- Mr. Lizhong DaiChairman of the Board & GM · born 1968
- Mr. Zhu PengCFO, Deputy GM & Director · born 1975
- Mr. Haixiao WangDeputy GM & Director · born 1978
- Mr. Kang WuDeputy GM & Director · born 1985
- Ms. Xiao Mei RenEmployee Director · born 1987
- Mr. Qiang HuangSecretary · born 1982
- Mr. Zhongping DengDeputy General Manager · born 1977
- Ms. Xiaoyan XiongDeputy General Manager · born 1983
- Mr. De Yong TanDeputy General Manager · born 1987
- Dr. Keya ZhangCore Technical Personnel · born 1985